Cargando…

Inhaled Dual Phosphodiesterase 3/4 Inhibitors for the Treatment of Patients with COPD: A Short Review

Current pharmacological treatments for chronic obstructive pulmonary disease (COPD) are mostly limited to inhaled bronchodilators and corticosteroids. Azithromycin can contribute to exacerbation prevention. Roflumilast, a phosphodiesterase (PDE) 4 inhibitor administered orally, also prevents exacerb...

Descripción completa

Detalles Bibliográficos
Autores principales:	Martin, Clémence, Burgel, Pierre-Régis, Roche, Nicolas
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8378910/ https://www.ncbi.nlm.nih.gov/pubmed/34429594 http://dx.doi.org/10.2147/COPD.S226688

Ejemplares similares

A dose-ranging study of the inhaled dual phosphodiesterase 3 and 4 inhibitor ensifentrine in COPD
por: Singh, Dave, et al.
Publicado: (2020)

The short-term bronchodilator effects of the dual phosphodiesterase 3 and 4 inhibitor RPL554 in COPD
por: Singh, Dave, et al.
Publicado: (2018)

Symptom Improvement Following Treatment with the Inhaled Dual Phosphodiesterase 3 and 4 Inhibitor Ensifentrine in Patients with Moderate to Severe COPD – A Detailed Analysis
por: Watz, Henrik, et al.
Publicado: (2020)

Dysfunctional lung anatomy and small airways degeneration in COPD
por: Martin, Clémence, et al.
Publicado: (2013)

Identification of Clinical Phenotypes Using Cluster Analyses in COPD Patients with Multiple Comorbidities
por: Burgel, Pierre-Régis, et al.
Publicado: (2014)

An attempt at modeling COPD epidemiological trends in France
por: Burgel, Pierre-Régis, et al.
Publicado: (2018)

Randomized controlled trials of pharmacological treatments to prevent COPD exacerbations: applicability to real-life patients
por: Pahus, Laurie, et al.
Publicado: (2019)

Roflumilast: first phosphodiesterase 4 inhibitor approved for treatment of COPD
por: Giembycz, Mark A, et al.
Publicado: (2010)

Phosphodiesterase (PDE)-4 Inhibitors and COPD Correlation with Cancer
por: Organtzis, John, et al.
Publicado: (2014)

Phosphodiesterase-4 Inhibitors for Non-COPD Respiratory Diseases
por: Kawamatawong, Theerasuk
Publicado: (2021)

Inhaled Phosphodiesterase 4 (PDE4) Inhibitors for Inflammatory Respiratory Diseases
por: Phillips, Jonathan E.
Publicado: (2020)

Are there specific clinical characteristics associated with physician’s treatment choices in COPD?
por: Roche, Nicolas, et al.
Publicado: (2019)

The inhaled phosphodiesterase 4 inhibitor GSK256066 reduces allergen challenge responses in asthma
por: Singh, Dave, et al.
Publicado: (2010)

Exacerbations of COPD
por: Pavord, Ian D, et al.
Publicado: (2016)

Tiotropium might improve survival in subjects with COPD at high risk of mortality
por: Burgel, Pierre-Régis, et al.
Publicado: (2014)

Concentration–QT Modeling Following Inhalation of the Novel Inhaled Phosphodiesterase‐4 Inhibitor CHF6001 in Healthy Volunteers Shows an Absence of QT Prolongation
por: Jolling, Koen, et al.
Publicado: (2019)

The Ongoing Quest for Predictive Biomarkers in Chronic Obstructive Pulmonary Disease
por: Regard, Lucile, et al.
Publicado: (2023)

Roflumilast, a Novel Phosphodiesterase 4 Inhibitor, for COPD Patients with a History of Exacerbations
por: Field, Stephen K.
Publicado: (2011)

Roflumilast, a phosphodiesterase-4 inhibitor, induces phagocytic activity in Greek COPD patients
por: Porpodis, Konstantinos, et al.
Publicado: (2015)

Two Distinct Chronic Obstructive Pulmonary Disease (COPD) Phenotypes Are Associated with High Risk of Mortality
por: Burgel, Pierre-Régis, et al.
Publicado: (2012)

Role of inhaled antibiotics in the era of highly effective CFTR modulators
por: Elborn, J. Stuart, et al.
Publicado: (2023)

Phosphodiesterase-4 Inhibitors for the Treatment of Inflammatory Diseases
por: Li, Heng, et al.
Publicado: (2018)

Airway Inflammatory/Immune Responses in COPD and Cystic Fibrosis
por: De Rose, Virginia, et al.
Publicado: (2018)

Erratum for “Roflumilast, a Novel Phosphodiesterase 4 Inhibitor, for COPD Patients with a History of Exacerbations”
Publicado: (2012)

Additive anti-inflammatory effects of corticosteroids and phosphodiesterase-4 inhibitors in COPD CD8 cells
por: Grundy, Seamus, et al.
Publicado: (2016)

Aspergillus fumigatus in the cystic fibrosis lung: pros and cons of azole therapy
por: Burgel, Pierre-Régis, et al.
Publicado: (2016)

Change in Lung Function after Initiation of Elexacaftor–Tezacaftor–Ivacaftor: Do Not Forget Anatomy!
por: Martin, Clémence, et al.
Publicado: (2022)

Association between occupational exposure and the clinical characteristics of COPD
por: Caillaud, Denis, et al.
Publicado: (2012)

Anti‐inflammatory effects of the novel inhaled phosphodiesterase type 4 inhibitor CHF6001 on virus‐inducible cytokines
por: Edwards, Michael R., et al.
Publicado: (2016)

A Dose-Ranging Study of the Novel Inhaled Dual PDE 3 and 4 Inhibitor Ensifentrine in Patients with COPD Receiving Maintenance Tiotropium Therapy
por: Ferguson, Gary T, et al.
Publicado: (2021)

Impact of current cough on health-related quality of life in patients with COPD
por: Deslee, Gaëtan, et al.
Publicado: (2016)

The Selective Phosphodiesterase 4 Inhibitor Roflumilast and Phosphodiesterase 3/4 Inhibitor Pumafentrine Reduce Clinical Score and TNF Expression in Experimental Colitis in Mice
por: Rieder, Florian, et al.
Publicado: (2013)

Apremilast: A Phosphodiesterase 4 Inhibitor for the Treatment of Psoriatic Arthritis
por: Mease, Philip J.
Publicado: (2014)

Relationship between blood eosinophils, clinical characteristics, and mortality in patients with COPD
por: Zysman, Maeva, et al.
Publicado: (2017)

Effect of the inhaled PDE4 inhibitor CHF6001 on biomarkers of inflammation in COPD
por: Singh, Dave, et al.
Publicado: (2019)

Clinical Implication of Phosphodiesterase-4-Inhibition
por: Schick, Martin Alexander, et al.
Publicado: (2022)

Impact of gender on COPD expression in a real-life cohort
por: Roche, Nicolas, et al.
Publicado: (2014)

The IMPACT of triple versus dual single-inhaler therapy on exacerbations of COPD
por: Dobler, Claudia C.
Publicado: (2018)

Phosphodiesterase 4 Inhibitors in Allergic Rhinitis/Rhinosinusitis
por: Janosova, Viera, et al.
Publicado: (2020)

CFTR Modulators in People with Cystic Fibrosis: Real-World Evidence in France
por: Regard, Lucile, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_58lvf9ghn0k6o7itu0ritd23l6